

## **AMENDMENTS TO THE CLAIMS**

### **Claim 1 (currently amended)**

A pharmaceutical combination composition consisting essentially of, as ~~the~~ ~~separate~~ active ingredients, a) a NO synthase inhibitory substance and b) a metabolic antioxidant substance possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support, said composition having the dual activity of inhibiting the NO synthase and antioxidant, a) and b) being in separated form.

### **Claims 2-3 (cancelled)**

### **Claim 4 (currently amended)**

A pharmaceutical composition of claim 1 wherein the metabolic ~~metabolix~~ antioxidant is selected from the group consisting of dithiothreitol, pyritinol, lipoic acid and its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine, and peptides comprising at least two cysteine residues.

### **Claims 5 to 7 (cancelled)**

**Claim 8 (previously presented)**

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of a compound of amino acid type, a compound of the guanidine isothiurea, nitro- and cyano-aryl, amino-pyridine, amino-pyrimidone, amidine, indazole and imidazole families.

**Claim 9 (previously presented)**

A pharmaceutical composition of claim 8 wherein the NO synthase inhibitor of amino-acid type is selected from the group consisting of L-arginine, ornithine and lysine derivatives.

**Claim 10 (previously presented)**

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl)phenylimidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophene-carboximidamine, S-ethylisothiurea, S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

**Claim 11** (previously presented)

A pharmaceutical composition of claim 1 wherein the metabolic antioxidant is lipoic acid in racemic or enantiomeric form.

**Claim 12** (previously presented)

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

**Claims 13-24** (cancelled)

**Claim 25-36** (cancelled)